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(ITV) approach was applied. To evaluate the clinical benefit 
of DTT, the tumor motion amplitude on 4DCT was compared 
to the mean maximal peak-to-peak amplitude on fluoroscopy 
sequences acquired during DTT and the difference in PTV 
volume (DTT versus ITV) was calculated. Treatment-related 
toxicity was scored according to the Common Terminology 
Criteria for Adverse Events v.4.0. 
Results: A total of 38 lesions were treated in 35 patients. The 
delivered dose schedules were as follows: 48Gy/4 fractions 
(n=32), 51Gy/3 fractions (n= 4), 60Gy/8 fractions (n=2). Mean 
superior-inferior (SI) motion exceeded 8 mm in 14 out of 38 
lesions. DTT was used for 7 lesions. Reasons for omitting DTT 
were: pulmonary function or lesion location not allowing 
visicoil insertion and history of prior pneumothorax. Mean 
treatment time for a DTT session was 28.6 minutes (20-34.8 
minutes). Mean SI motion on 4DCT in DTT lesions was 11.8 
mm (8.6-16.9 mm). The mean maximal peak-to-peak 
amplitude observed during fluoroscopy was 20.4 mm (8.2-
50.5 mm) demonstraing a significant variability in respiration 
induced tumor motion. DTT achieved a median reduction of 
58% in PTV volume. With a median follow-up of 7 months (3-
19 months), 1 local failure was observed in a centrally 
located lesion treated with an ITV approach. Only 1 patient 
experienced a grade 2 radiation pneumonitis and 2 patients 
presented with a COPD exacerbation in the weeks following 
radiation. No toxicity was observed in the patients treated 
with DTT. 
Conclusions: DTT with the Vero4DRT system using a single 
fiducial marker proved to be clinically feasible and safe. DTT 
can be performed in an acceptable time frame, is able to 
account for respiratory variability and results in a substantial 
reduction in PTV volume.  
(1) Matsuo Y, Ueki N, Takayama K, et al. Evaluation of 
dynamic tumour tracking radiotherapy with real-time 
monitoring for lung tumours using a gimbal mounted linac. 
Radiother Oncol 2014.  
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Purpose/Objective: Background: During the last decade, 
several studies have established predictive models for normal 
tissue radiosensitivity based on multiple SNPs (1-8). 
Typically, these studies assessed a limited number of SNPs. 
For some of these SNPs, a ‘risk allele’ was defined and the 
studies then looked for an association between the total 
number of risk alleles and normal tissue complication risk. 
Even though many of these models have yielded highly 
significant results, the models have often been inconsistent 
with each other (table 1). This probably relates to the way 
these models were constructed. The process had three steps: 
1) For each of the included SNPs, a risk allele (minority vs. 
majority allele) was defined based on the observation that it 
was (often non-significantly) associated with the outcome 
parameter of the study (radiosensitivity). 2) A model was 
established based on these risk alleles. 3) A statistical test 
was carried out to determine if the number of risk alleles was 
significantly associated with radiosensitivity (the same 
parameter as used for the selection of the risk alleles). By 
doing so, a circularity is introduced into the analysis that 
makes it likely that random fluctuations (for the individual 
SNPs) are amplified into significant associations (for the 
entire model). 
Materials and Methods: In order to further explore this 
potential problem, we reanalyzed the dataset originally used 
to establish the multiple SNP model published by Andreassen 
et al. in 2003 (1). Instead of the actual SNP genotypes we 
randomly assigned ‘genotypes’ to the patients for 7 fictitious 
SNPs that had the same relative distribution as the SNPs in 
the original dataset. Subsequently, we selected risk alleles 
for these ‘SNPs’ and established a multiple SNP model 
exactly as in the original study. This procedure was repeated 
10 times.  
Results: In 8 out of 10 times a significant result was found for 
the model. This clearly demonstrates that the process of 
actively fitting the model to the dataset is indeed per se 
capable of producing nominally significant results for the 
entire model. 
Conclusions: Great caution should be taken when a 
predictive model is established and tested within the same 
patient cohort. A significant finding for a multiple SNP model 
established in this way cannot be used to indirectly validate 
the underlying SNPs. Thus, we have to establish robust 
associations for the individual SNPs that can be entered into 
a predictive multiple SNP model that should finally be 
validated in an independent dataset. 
 
 
References: (1) Andreassen CN. R&O 2003;69:127-135. (2) 
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Purpose/Objective: Rectal bleeding is one of the common 
radiation-induced complications following radiotherapy in 
prostate cancer patients, which can greatly impair the 
quality of life for cancer survivors. The purpose of this study 
was to investigate whether single nucleotide polymorphisms 
(SNPs) are associated with susceptibility to late rectal 
bleeding in men treated with radiotherapy for prostate 
cancer using a genome-wide association study (GWAS) 
dataset. 
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Materials and Methods: There were 365 evaluable patients 
with at least one year of follow-up for the development of 
rectal bleeding. Rectal bleeding was assessed using the 
Radiation Therapy Oncology Group (RTOG) late radiation 
morbidity scoring schema. There were 74 patients with Grade 
2 or more late rectal bleeding. For all patients, DNA was 
genotyped using Affymetrix Genome-Wide Human SNP Array 
6.0. A quality control test was performed with SNP missing 
rate > 5%, minor allele frequency (MAF) < 5%, and Hardy-
Weinberg equilibrium (p < 10E-5). As a result, 613,496 SNPs 
remained. For the analysis, we split the patients into two 
groups: a group of patients with Grade 0 or 1 late rectal 
bleeding and the other group of patients with Grade 2 or 
more.  
To predict late rectal bleeding toxicity, we designed a 
machine learning-based multi-SNP model. Our model mainly 
consists of two steps: in the first step, principal component 
analysis (PCA) is used to filter out irrelevant SNPs and in the 
second step L1-penalized regression (LASSO) is used to 
remove redundant SNPs and to build a sparse regression 
model. In particular, normal tissue complication probability 
(NTCP), which was calculated using logistic regression with a 
few principal components derived from the first step, was 
used as a response variable in the second step. For unbiased 
assessment of the predicted model, the dataset was split into 
two groups: training dataset (2/3 of samples) and validation 
dataset (1/3 of samples). In the model design, only the 
training dataset was used with 10-fold cross validation. After 
50 iterations of the proposed method, SNPs were ranked 
based on the frequency that each SNP was used in the LASSO 
models. In a manner of forward feature selection, the 
validation dataset was tested with the LASSO models that 
were constructed using the training dataset. The area under 
the receiver operating characteristic (ROC) curve (AUC) was 
used as a performance metric. 
Results: Using the training data, univariate analysis was 
performed using Chi-square test. With a threshold of 
p=0.001, 749 SNPs remained. These SNPs were fed into our 
model. The cross-validation with the training dataset 
resulted in AUC=0.85 (standard deviation: 0.02) and the best 
final model with the validation dataset resulted in AUC=0.68 
(p=0.004) with 360 SNPs as shown in Fig. 1. 
 
Conclusions: A novel machine learning method demonstrated 
that a large number of SNPs contribute to clinical 
radiosensitivity for the radiation-induced late rectal 
bleeding. However, evaluation on other datasets is necessary 
to validate our model.  
   
OC-0083   
ATM rs189037 associates with DLCO change in patients 
with lung cancer treated with radiation therapy 
Y. Song1, D. Gomez1, J.L. Lopez Guerra2, Y. Zhuang1, Q. 
Nguyen1, L. Levy1, X. Ting1, Z. Liao1 
1The University of Texas MD Anderson Cancer Center, 
Radiation Oncology, Houston, USA  
2University Hospital Virgen del Rocio, Radiation Oncology, 
Sevilla, Spain  
 
Purpose/Objective: Single-nucleotide polymorphisms (SNPs) 
in the ataxia telangiectasia mutated (ATM) gene have been 
associated with clinical radiation pneumonitis, but those 
findings have not been correlated with the pulmonary 
function impairment. Therefore, we investigated the 
association between SNPs in the ATM gene and the risk of 
diffusing capacity of the lung for carbon monoxide (DLCO) 
change in patients with non–small-cell lung cancer (NSCLC) 
treated with radiation therapy (RT).  
Materials and Methods: From November 1998 through June 
2009, 448 consecutive patients with inoperable or 
unrespectable primary NSCLC underwent definitive (≥60 Gy) 
radio(chemo)therapy; exclusion criteria were patients with a 
history of thoracic surgery, RT, or lung cancer or those who 
did not have undergone pulmonary function test before and 
after RT within one year. Ultimately, 100 patients met the 
selection criteria for this study. We genotyped two SNPs of 
the ATM gene (rs189037 and rs228590), and assessed 
correlation with DLCO impairment using logistic regression 
analysis. 
Results: The dataset consisted of 58 men and 42 women, 
with a median age of 64 years (range, 38–83 years). Of all 
these patients, 86 were whites and 82% had stage III/IV 
diseases according to the 6th edition of the AJCC stage 
grouping criteria. The median mean lung dose was 17.5 Gy 
(range, 4.7–29.5 Gy). Median DLCO change within one year 
after RT was 0.81 (range 0.22-1.79). Early DLCO change (3-6 
months after RT) had the same range but the median value 
was 0.77. The genotype distribution of all studied SNPs was: 
rs189037, 29% AA, 49% AG, 22% GG; and rs228590, 33% CC, 
49% CT, 19% TT. Univariate and multivariate analyses showed 
that the AA genotype of ATM rs189037 was associated with 
significantly higher DLCO impairment after definitive 
radiation than the GG/AG genotypes (univariate beta 
regression coefficient -0.12; 95% confidence interval [CI], -
0.24~-0.008; P = 0.037; multivariate beta regression 
coefficient -0.10; 95% CI, -0.20~-0.005; P = 0.04). However, 
similar results were not observed for rs228590 (univariate 
beta regression coefficient -0.10; 95% CI, -0.25~-0.12; P = 
0.096). 
Conclusions: The AA genotype of ATM rs189037 was 
associated with higher risk of lung injury, compared with the 
GG/AG genotypes in patients with NSCLC treated with 
radio(chemo)therapy. This response marker may be used for 
guiding therapy intensity in an individual patient, which 
would further the goal of individualized therapy.  
   
OC-0084   
SNP analysis on late radiation induced toxicity analyzed by 
anal physiological methods in prostate cancer patients 
L.H. Schack1, S.E. Petersen2, L. Lundby3, M. Hoyer2, L. 
Bentzen2, J. Overgaard1, C.N. Andreassen2, J. Alsner1 
1Aarhus University Hospital, Experimental Clinical Oncology, 
Aarhus C, Denmark  
2Aarhus University Hospital, Oncology, Aarhus C, Denmark  
3Aarhus University Hospital, Surgery, Aarhus C, Denmark  
 
Purpose/Objective: Normal tissue toxicity sets the dose limit 
for radiotherapy (RT) in cancer treatment and hence has 
significance for its curative potential. Individual differences 
in the severity of radiation induced toxicity suggests that 
there is a possibility of dose escalation to the more 
radioresistant group. In theory prediction of individual 
radiosensitivity could augment cure rates of RT. From a 
previous study we have access to a cohort of 42 prostate 
cancer patients treated with External Beam RT (EBRT) and 
clinical data for radiation induced toxicity measured by anal 
